

Appointment of Non-Executive Directors

Maureen Baker and Carl Stubbings to join the Board as Non-Executive Directors.

Melbourne, Australia, 26 August 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company, is pleased to announce the appointment of Ms Maureen Baker and Mr Carl Stubbings as Non-Executive Directors of the Company, effective 27 August 2026.

About – Maureen Baker

Maureen is a senior capital markets professional with over 25 years' experience in a variety of financial services roles in the investment banking and securities industry. She is currently a Non-Executive Director of Acorn Capital Investment Fund Limited (ASX: ACQ), where she chairs the Risk and Audit Committee and is also a Non-Executive Director of Vmoto Ltd (ASX: VMT).

Maureen previously served as the Head of Regional Equity Sales for Deutsche Bank in Hong Kong, covering the Asia-Pacific markets and investors. She has also served in the role of Managing Director, Australian Sales at CLSA, together with other investment banking roles following her return to Australia.

Maureen holds a Bachelor of Commerce from the University of Melbourne and an MBA from Melbourne Business School and is a Graduate of the Australian Institute of Company Directors.

About – Carl Stubbings

Carl is an experienced biotechnology and diagnostics executive with extensive experience in the commercialisation of diagnostic products, including sales, marketing and business development in Australia and international markets.

Carl spent 13 years in the USA, where he served as Senior Vice President of Panbio USA Ltd and Vice President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics (NASDAQ: DGX).

Since returning to Australia, Carl has held a number of executive roles, including Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC), CEO and Managing Director of Sienna Cancer Diagnostics Ltd (ASX: SDX), Chief Operating Officer of BARD1 (ASX: IIQ) and Chief Commercial Officer of Genetic Technologies (ASX: GTG, NASDAQ: GENE).

Carl is currently fractional CEO of Aptium AI, Non-Executive Director of Sangui Bio, Chair of Diag-Nose Medical and Chair of InGeNA, the Industry Genomics Network Alliance.

Carl holds a Bachelor of Applied Science (Medical Technology) from Queensland University of Technology.

Rhythm Biosciences Ltd

ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

Rhythm Non-Executive Chairman, Gavin Fox-Smith, commented:

“On behalf of the Board, I am delighted to welcome Maureen and Carl to Rhythm. They each bring extensive experience and highly complementary skills that will further strengthen the Board as the Company continues to advance its commercialisation strategy.

Maureen’s deep capital markets and investor experience will be particularly valuable as Rhythm continues to execute its strategy, while Carl brings significant commercial and operational experience across the biotech and diagnostics sectors, including the commercialisation of diagnostic products in Australia and international markets.”

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience’s simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.